What is it about?

COBALT is a clinical trial, which aims to find out if adding Memantine to a cholinesterase inhibitor (either donepezil, rivastigmine, and galantamine) improves overall health and functioning for people with Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia. (PDD)

What is involved?

Participants will be assigned to either the treatment group or the placebo where they will be asked to take the medication for 52 weeks and be monitored for safety. They will have regular contact with the SABP research team throughout the study.

Who can take part?

Please get in contact if you are 50 + years, have a diagnosis of Parkinson's Disase Dementia (PDD) or Dementia with Lewy Bodies (DLB. 

Get in contact with our team on 01372 216584 or email research@sabp.nhs.uk